PROGRAM BOOK

SUNDAY | PROGRAM DETAILS | SUNDAY, MARCH 6, 2016
How to Accelerate Basic Discoveries to
Patient Benefit
Coronado L
ORGANIZERS: Jeffrey C. Lotz, PhD, University of California at
San Francisco; Vijay K. Goel, PhD, University of Toledo
There is an implicit expectation that advancements in biomedical
research will lengthen and improve the quality of life. This
premise underlies investments in basic research that continue
to yield important advances. However, the clinical translation
of new discoveries is often impeded by a number of transdisciplinary
obstacles. On the academic side, traditional funding
and promotion mechanisms encourage scientists to continually
push the frontiers of basic science, rather than refine existing
concepts along a translational track. From a clinical perspective,
many new technologies are not sufficiently aligned with specific
clinical indications, and lack validation in appropriate pre-clinical
models. Also, academic scientists and clinicians often lack
expertise and the clear roadmap necessary to bring medical
products to market. On the industry side, product development
and clinical trials represent a significant financial burden,
requiring that products not only be therapeutically effective
but also commercially successful. This necessitates addressing
specific unmet needs with high potential for regulatory approval,
clinical adoption, and payer reimbursement. Taken together,
these factors limit the opportunities for patients to experience the
life-enhancing benefits of many basic discoveries that are never
developed into products that can be brought to market.
This workshop will discuss the opportunities and roadblocks
associated with translating basic discoveries to clinical benefit.
Presentations will be followed by a panel discussion with
audience participation.
AAOS Research Priorities
Tamara Alliston, PhD, University of California San Francisco
Measuring Value in the Management of
Musculoskeletal Disorders
Sigurd Berven, University of California San Francisco
Industry Perspective on New Technology Selection
and Investment
Hassan Serhan, Depuy Synthes Spine
NIH Initiatives to Accelerate Discoveries to
Clinical Trials
Joan McGowan, PhD, NIAMS/NIH, DHHS-Musco Diseases Branch
PROFESSIONAL ADVANCEMENT SESSION:
Healthcare Economics in Orthopaedics—
What You Need to Know*
Coronado K
Organized by the ORS Industry Engagement Committee
ORGANIZERS: Michael Ominsky, PhD, Amgen, Inc.;
Sally LiArno, PhD, Stryker Orthopaedics
The development of any new orthopaedic implant or therapeutic
is dependent on eventual reimbursement to the company for
its use. Therefore understanding at an early stage the scope of
the unmet medical need that the product is targeting and its
potential value to patients, physicians, and insurance/payers is
critical. Similarly, the economic impacts of disease drive both
basic and translational research in academic settings and are an
important component of grant funding. Despite its importance,
orthopaedic researchers and physicians are rarely exposed to the
ways in which healthcare economics are examined and applied
to develop new products or drive new areas of research. The goal
of this workshop is to educate the audience on what healthcare
economics means within orthopaedics, and provide examples of
how it is applied to stimulate new areas of research.
The Burden of Musculoskeletal Disease and the Change
in Reimbursement from Volume to Value
Stuart Weinstein, MD, University of Iowa Medical Center
Data Overload: Resources for Evaluating Utilization,
Outcomes, and Costs
Kevin Ong, Exponent, Inc.
Value Based Healthcare from Theory to Practice
Bipin Mistry, MD, MBA, Harvard Business School
*This session does not qualify for CME credit
SUNDAY
35